Coda Therapeutics Inc

CoDa Therapeutics is a biopharmaceutical company focused on the development and commercialization of a new generation of wound care therapeutics known as “gap junction modulators.”

The company’s Gap Junction Modulation technology targets the cell-to-cell communication that leads, amongst other things, to cell death in the initial phases of wound-healing following an injury.

More about us

CoDa Therapeutics Announces Positive Results from Phase 2b Study of NEXAGON® in Chronic Venous Leg Ulcers

SAN DIEGO, California - January 8, 2013
CoDa Therapeutics, Inc. today announced positive results from a Phase 2b clinical trial of NEXAGON® in patients with chronic venous leg ulcers. NEXAGON® is an easy to administer, once-a-week, topical, drug candidate being developed for the treatment of chronic wounds. It is designed to increase the incidence of wound healing compared to existing therapeutic techniques, and to heal them much faster. The company believes these results support advancing NEXAGON into Phase 3 registration trials. Venous leg ulcers are increasingly common and costly, and can be a cause of prolonged suffering for patients...

More...

CoDa Therapeutics Completes $49 Million Fund Raising .

July 24, 2012

AUCKLAND – CoDa Therapeutics, Inc. announced today that it raised an additional NZ$24.5M from Russian investment firm RusnanoMedInvest (“RMI”). This brings the company’s total Series B Round to nearly NZ$49 million following a first close late last year...

More...

Square 1 Announces $6 Million Credit Facility to CoDa Therapeutics, Inc.

SAN DIEGO, California - October 6, 2011
Square 1 Bank, the exclusive banking partner to entrepreneurs and the venture capital community, is pleased to partner with CoDa Therapeutics, Inc. in providing a $6 million term loan...

More...

CoDa Therapeutics Appoints Chief Medical Officer

San Diego, California – May 2, 2011
CoDa Therapeutics, Inc. announced today that it has named David E. Eisenbud, MD, as CMO (Chief Medical Officer). The appointment of Dr. Eisenbud is key to...

More...

CoDa Therapeutics Closes $19 Million Series B Financing Round

San Diego, California - April 18, 2011
CoDa Therapeutics, Inc. announced today that it has raised $19.2 million in a Series B financing. Current investors Domain Associates, GBS Venture Partners...

More...

CoDa Therapeutics Achieves Positive Phase 2 Efficacy of NEXAGON® in Chronic Venous Leg Ulcers

San Diego, California, May 25, 2010 – CoDa Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair, today...

More...